Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases

Journal of Physiology and Pharmacology

Volumn 66, Issue 4, 2015, Pages 483-491

  Konturek, Peter C ^a   Haziri, D ^a   Brzozowski, T ^b   Hess, T ^a   Heyman, S ^a   Kwiecien, S ^b   Konturek, S J ^b   Koziel, J ^c  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Brain gut axis; Clostridium difficile; Fecal microbiota transplantation; Functional gastrointestinal disorders; Gut microbiota; Inflammatory bowel disease; Irritable bowel syndrome

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1; TUMOR NECROSIS FACTOR ALPHA;

AGING; ANTIMICROBIAL THERAPY; ATHEROSCLEROSIS; CLOSTRIDIUM DIFFICILE INFECTION; DIABETES MELLITUS; DISEASE ASSOCIATION; FECES ANALYSIS; FECES MICROFLORA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; METABOLIC REGULATION; METABOLIC SYNDROME X; MICROBIAL DIVERSITY; MICROBIOTA TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; TREATMENT OUTCOME; ANIMAL; FECES; GASTROINTESTINAL DISEASES; MICROBIOLOGY;

ANIMALS; FECES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 84940750563     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Savel RH, Munro CL. From Asclepius to Hippocrates: the art and science of healing. Am JCrit Care2014; 23: 437-439.
2. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology2014; 146: 1449-1458.
3. Power SE, O'Toole PW, Stanton C, Ross RP, Fitzgerald GF. Intestinal microbiota, diet and health. Br J Nutr 2014; 111: 387-402.
4. Cani PD, Everard A. Talking microbes: when gut bacteria interact with diet and host organs. Mol Nutr Food Res 2015; Jul 16: doi: 10.1002/mnfr.201500406(epub ahead of print).
5. Petschow B, Dore J, Hibberd P, et al.Probiotics, prebiotics, and the host microbiome: the science of translation. Ann NY Acad Sci 2013; 1306: 1-17.
6. Sun J, Chang EB. Exploring gut microbes in human health and disease: Pushing the envelope. Genes Dis 2014; 1: 132-139.
7. Arumugam M, Raes J, Pelletier E, et al.Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
8. Claesson MJ, Cusack S, O'Sullivan O, et al.Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011; 108 (Suppl. 1): 4586-4591.
9. Simren M. IBS with intestinal microbial dysbiosis: a new and clinically relevant subgroup? Gut2014; 63: 1685-1686.
10. Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R. How the intricate interaction among Toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology. J Immunol Res 2015; 2015: 489821.
11. Pandolfi F, Cianci R, Pagliari D, Landolfi R, Cammarota G. Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases. Mediators Inflamm 2009; 2009: 132028.
12. Geremia A, Biancheri, Allan P, Corazza GR, di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev2014; 13: 3-10.
13. Goulet O. Potential role of the intestinal microbiota in programming health and disease. Nutr Rev2015; 73 (Suppl. 1): 32-40.
14. Lankelma JM, Nieuwdorp M, de Vos WM, Wiersinga WJ. The gut microbiota in internal medicine: implications for health and disease. Neth J Med2015; 73: 61-68.
15. Schippa S, Conte MP. Dysbiotic events in gut microbiota: impact on human health. Nutrients2014; 6: 5786-5805.
16. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011; 62: 591-599.
17. Burokas A, Moloney RD, Dinan TG, Cryan JF. Microbiota regulation of the mammalian gut-brain axis. Adv Appl Microbiol 2015; 91: 1-62.
18. Bercik P, Collins SM, Verdu EF. Microbes and the gut-brain axis. NeurogastroenterolMotil2012; 24: 405-413.
19. Al-Lahham SH, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. Biochim Biophys Acta 2010; 1801: 1175-1183.
20. Zoetendal EG, de Vos WM. Effect of diet on the intestinal microbiota and its activity. Curr Opin Gastroenterol 2014; 30: 189-195.
21. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res1994; 54: 3288-3293.
22. Heerdt BG, Houston MA, Augenlicht LH. Short-chain fatty acid-initiated cell cycle arrest and apoptosis of colonic epithelial cells is linked to mitochondrial function. Cell GrowthDiffer1997; 8: 523-532.
23. Shoaie S, Nielsen J. Elucidating the interactions between the human gut microbiota and its host through metabolic modeling. Front Genet2014; 5: 86.
24. Tilg H, Moschen AR. Food, Immunity, and the microbiome. Gastroenterology2015; 148: 1107-1119.
25. Hamilton MK, Boudry G, Lemay DG, Raybould HE. Changes in intestinal barrier function and gut microbiota in high-fat diet-fed rats are dynamic and region dependent. Am JPhysiol Gastrointest Liver Physiol2015; 308: G840-G851.
26. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis1999; 5: 262-270.
27. Mondot S, de Wouters T, Dore J, Lepage P. The human gut microbiome and its dysfunctions. Dig Dis 2013; 31: 278-285.
28. DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. NatRev Gastroenterol Hepatol2011; 8: 523-531.
29. Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology 2015; 148: 30-36.
30. Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol2013; 10: 637-644.
31. DuPont HL. Therapeutic effects and mechanisms of action of rifaximin in gastrointestinal diseases. Mayo Clin Proc2015; 90: 116-1124.
32. Zapata HJ, Quagliarello VJ. The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc2015; 63: 776-781.
33. Hermann-Bank ML, Skovgaard K, Stockmarr A, Larsen N, Molbak L. The gut microbiotassay: a high-throughput qPCR approach combinable with next generation sequencing to study gut microbial diversity. BMC Genomics2013; 14: 788.
34. Vaughan EE, Heilig H, Ben-Amor K, de Vos WM. Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches. FEMS Microbiol Rev2005; 29: 477-490.
35. Rehman T. Role of the gut microbiota in age-related chronic inflammation. Endocr MetabImmune Disord Drug Targets2012; 12: 361-367.
36. Mariat D, Firmesse O, Levenez F, et al.The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol2009; 9: 123.
37. Keller JM, Surawicz CM. Clostridium difficile infection in the elderly. Clin Geriatr Med2014; 30: 79-93.
38. Biagi E, Candela M, Franceschi C, Brigidi P. The aging gut microbiota: new perspectives. Ageing Res Rev2011; 10: 428-429.
39. Biagi E, Candela M, Turroni S, Garagnani P, Franceschi C, Brigidi P. Ageing and gut microbes: perspectives for health maintenance and longevity. Pharmacol Res2013; 69: 11-20.
40. Keller JJ, Kuijper EJ. Treatment of recurrent and severe Clostridium difficile infection. Annu Rev Med2015; 66: 373-86.
41. Korman TM. Diagnosis and management of Clostridium difficile infection. Semin RespirCrit Care Med2015; 36: 31-43.
42. Czepiel J, Biesiada G, Brzozowski T, et al.The role of local and systemic cytokines in patients infected with Clostridium difficile. J Physiol Pharmacol2014; 65: 695-703.
43. Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect2012; 18 (Suppl. 6): 5-12.
44. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA2015; 313: 398-408.
45. Tacke D, Wisplinghoff H, Kretzschmar A, et al.First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe. Clin Microbiol Infect 2015; Jul 7: S1198-743X(15)00689-8(epub ahead of print).
46. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology2013; 145: 946-953.
47. Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol2013; 108: 177-185.
48. Eiseman B, Silen W, Bascom CS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery1958; 44: 854-859.
49. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology 2015; 149: 223-237.
50. Satokari R, Mattila E, KainulainenV, Arkkila PE. Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection - an observational cohort study. Aliment Pharmacol Ther2015; 41: 46-53.
51. Koenigsknecht MJ, Young VB. Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs. Curr Opin Gastroeuterol 2013; 29: 628-632
52. van Nood E, Vrieze A, Nieuwdorp M, et al.Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med2013; 368: 407-415.
53. Song Y, Garg S, Girotra M, et al.Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One2013; 8: e81330.
54. Petrof EO, Gloor GB, Vanner SJ, et al.Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating'the gut. Microbiome2013; 1: 3.
55. Petrof EO, Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology2014; 146: 1573-1582.
56. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am2015; 29: 109-122.
57. Alang N, Kelly CR. Weight gain after fecal microbiota transplantation. Open Forum InfectDis 2015; 2: ofv004. doi: 10.1093/ofid/ofv004.
58. Kelly CR, Ihunnah C, Fischer M, et al.Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol2014; 109: 1065-1071.
59. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol 2015; 37: 47-55.
60. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis2014; 8: 1569-1581.
61. Rossen N, Fuentes S, van der Spek M, et al. Findings from randomized controlled trial of faecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149: 110-118.
62. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology 2014; 146: 1554-1563.
63. Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physio 2013; 305: G529-G541.
64. Dylag K, Hubalewska-Mazgaj M, Surmiak M, Szmyd J, Brzozowski T. Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders. Curr Pharm Des 2014; 20: 1149-1155.
65. Dinan TG, Stilling RM, Stanton C, Cryan JF. Collective unconcious: how gut microbes shape human behaviour. JPsychiatr Res2015; 63: 1-9.
66. Siuda D, Wu Z, Chen Y, et al.Social isolation-induced epigenetic changes in midbrain of adult mice. J Physiol Pharmacol2014; 65: 247-255.
67. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil2015; 27: 19-29.
68. Fierbinteanu-Braticevici C. Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J Physiol Phamacol2013; 64: 3-9.
69. Parekh PJ, Arusi E, Vinik AI, Johnson DA. The role and influence of gut microbiota in pathogenesis and management of obesity and metabolic syndrome. Front Endocrinol (Lausanne) 2014; 5: 47.
70. Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest 2011; 121: 2126-2132.
71. Vrieze A, Van Nood E, Holleman F, et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.
72. Fischer M, Sipe, BW, Rogers NA, et al.Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther2015; 42: 470-476.